Chk1/2和Plk1蛋白在子宫内膜癌中的表达

Expressions of Chk1/2 and Plk1 Protein in Endometrial Carcinoma

目的Chk1/2(checkpoint kinase1、2)和Plk1(polo-like kinase1)是各细胞周期检测点启动DNA损伤修复的主要激酶,本研究检测3种激酶在子宫内膜癌及正常子宫内膜组织中的表达,探讨3种蛋白在两者之间的表达差异、与子宫内膜癌临床病理特征的关系及3种蛋白表达的相关性。方法应用免疫组化SP法检测44例子宫内膜癌组织和21例正常子宫内膜组织中Chk1、Chk2和Plk1蛋白的表达情况。结果Chk1、Chk2和Plk1蛋白在子宫内膜癌患者中的阳性率分别为47.7%、75.0%和31.8%,在正常子宫内膜中的阳性率分别为61.9%、61.9%和4.8%;Plk1蛋白在子宫内膜癌组织中的表达显著高于正常子宫内膜组织(P<0.01),而Chk1、Chk2的表达差异无统计学意义(P>0.05)。Chk1、Chk2和Plk1蛋白的表达在不同年龄、病理类型和临床分期的子宫内膜癌患者中差异无统计学意义(P>0.05);但Chk1的表达在不同分化程度的子宫内膜癌患者中差异有统计学意义(P<0.01)。Spearman等级相关分析,在44例子宫内膜癌患者中,Chk2与Plk1间的表达呈正相关(r=0.482,P=0.001)。结论Plk1可能成为子宫内膜癌比较理想的治疗靶点,而CHK1/2在子宫内膜癌中表达及意义还有待进一步研究。

Objective Chk1/2 （checkpoint kinase 1/2） and Plkl（polo-like kinase 1）play the major role in cell cycle checkpoint block when DNA lesion are emerged, this study was to investigate the expression of these kinases in endometrial carcinoma and healthy endometria, and to explore their relationships with clinical pathology parameters of endometrial carcinoma and the correlations among three kinases. Methods Immunohistochemistry was applied to detect the expressions of Chk1, Chk2 and Plkl in 44 cases of endometrial carcinoma and 21 cases of healthy endometria. Results The positive percentages of Chk1, Chk2 and Plk1 were 47. 7% 75.0% and 31.8% respectively in endometrial carcinoma, and were 61.9%, 61.9% and 4. 8% respectively in healthy endometria; The expression of plkl proteins in endometrial carcinoma was higher than that in healthy endometria, and the difference of plkl was significant （P〈0. 01）, while the expression differences of Chkl and chk2 were no significant （P〉0. 05）. The expressions of Chk1, Chk2 and Plk1 were not associated with the age, pathology and clinical stage of endometrial carcinoma patients （P〉0. 05）, while Chkl expressions associated with differentiation of endometrial carcinoma （P〈0.05）. In 44 endometrial carcinoma cases, Chk2 was positively correlated with plkl （r= 0. 482, P = 0. 001）. Conclusion Plkl might be ideal targets for endometrial carcinoma therapy,while the expressions and signifieanees of CHK1/2 in endometrial carcinoma need further research.